Prevalence and management of familial hypercholesterolæmia in patients with acute coronary syndromes

European Heart Journal

Volumn 36, Issue 36, 2015, Pages 2438-2445

  Nanchen, David ^a   Gencer, Baris ^b   Auer, Reto ^a   Räber, Lorenz ^c   Stefanini, Giulio G ^c   Klingenberg, Roland ^d   Schmied, Christian M ^d   Cornuz, Jacques ^a   Muller, Olivier ^e   Vogt, Pierre ^e   Jüni, Peter ^f   Matter, Christian M ^d   Windecker, Stephan ^c   Lüscher, Thomas F ^d   Mach, François ^b   Rodondi, Nicolas ^c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

acute coronary syndrome; cardiovascular prevention; Familial hypercholesterol mia; premature atherosclerosis; quality of care

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ACUTE CORONARY SYNDROME; ADULT; AGE; ALGORITHM; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG MEGADOSE; FAMILIAL DISEASE; FAMILIAL HYPERCHOLESTEROLAEMIA; FAMILY HISTORY; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); PATIENT HISTORY OF THERAPY; PATIENT INFORMATION; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVOR; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; MULTICENTER STUDY; SWITZERLAND;

ACUTE CORONARY SYNDROME; ANALYSIS OF VARIANCE; ATHEROSCLEROSIS; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PREVALENCE; PROPROTEIN CONVERTASES; QUALITY OF HEALTH CARE; SERINE ENDOPEPTIDASES; SWITZERLAND;

EID: 84942092305     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv289     Document Type: Article

References (28)

1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A. Familial hypercholesterolæmia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-3490a
2. Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012;97:3956-3964
3. Hovingh GK, Davidson MH, Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolæmia. Eur Heart J 2013;34:962-971
4. Marks D, Thorogood M, Neil HA W, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolæmia. Atherosclerosis 2003; 168:1-14
5. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care of familial hypercholesterolæmia from the International FH Foundation. Int J Cardiol 2014;171:309-325
6. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, National Lipid Association Expert Panel on Familial H. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S9-S17
7. European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF,Wood D. ESC/EAS Guidelines for the management of dyslipidæmias: the Task Force for the management of dyslipidæmias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818
8. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolæmia. BMJ 1991;303: 893-896
9. Wierzbicki AS, Humphries SE, Minhas R, Guideline Development G. Familial hypercholesterolæmia: summary of NICE guidance. BMJ 2008;337:a1095
10. Foody JM. Familial Hypercholesterolemia: an under-recognized but significant concern in cardiology practice. Clin Cardiol 2014;37:119-125
11. Robinson JG, Goldberg AC, National Lipid Association Expert Panel on Familial H. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S18-S29
12. Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, Abbink EJ, Stalenhoef AF, Visseren FL. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis 2010;209:189-194
13. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolæmia: a long term cohort study. BMJ 2008;337:a2423
14. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, Investigators OLT. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-1499
15. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schæfer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85: 2025-2033
16. Dorsch MF, Lawrance RA, Durham NP, Hall AS. Familial hypercholesterolæmia is underdiagnosed after AMI. BMJ 2001;322:111
17. Auer R, Gencer B, Raber L, Klingenberg R, Carballo S, Carballo D, Nanchen D, Cornuz J, Vader JP, Vogt P, Juni P, Matter CM, Windecker S, Luscher TF, Mach F, Rodondi N. Quality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medications. PLoS ONE 2014; 9:e93147
18. Gencer B, Auer R, Nanchen D, Raber L, Klingenberg R, Carballo D, Blum M, Vogt P, Carballo S, Meyer P, Matter CM, Windecker S, Luscher TF, Mach F, Rodondi N. Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis 2015;239:118-124
19. Klingenberg R, Heg D, Raber L, Carballo D, Nanchen D, Gencer B, Auer R, Jaguszewski M, Stahli BE, Jakob P, Templin C, Stefanini GG, Meier B, Vogt P, Roffi M, Maier W, Landmesser U, Rodondi N, Mach F, Windecker S, Juni P, Luscher TF, Matter CM. Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. Heart 2015;101:854-863
20. Civeira F, International Panel on Management of Familial H. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68
21. Gaudet D, Vohl MC, Julien P, Tremblay G, Perron P, Gagne C, Bergeron J, Moorjani S, Despres JP. Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians. Am J Cardiol 1998;82:299-305
22. Williams RR, Hopkins PN, Hunt SC, Wu LL, Hasstedt SJ, Lalouel JM, Ash KO, Stults BM, Kuida H. Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah. Arch Intern Med 1990;150:582-588
23. Do R, Stitziel NO, Won HH, Jorgensen AB, Duga S, Angelica Merlini P, Kiezun A, Farrall M, Goel A, Zuk O, Guella I, Asselta R, Lange LA, Peloso GM, Auer PL, Project NES, Girelli D, Martinelli N, Farlow DN, DePristo MA, Roberts R, Stewart AF, Saleheen D, Danesh J, Epstein SE, Sivapalaratnam S, Hovingh GK, Kastelein JJ, Samani NJ, Schunkert H, Erdmann J, Shah SH, Kraus WE, Davies R, Nikpay M, Johansen CT, Wang J, Hegele RA, Hechter E, Marz W, Kleber ME, Huang J, Johnson AD, Li M, Burke GL, Gross M, Liu Y, Assimes TL, Heiss G, Lange EM, Folsom AR, Taylor HA, Olivieri O, Hamsten A, Clarke R, Reilly DF, Yin W, Rivas MA, Donnelly P, Rossouw JE, Psaty BM, Herrington DM, Wilson JG, Rich SS, Bamshad MJ, Tracy RP, Cupples LA, Rader DJ, Reilly MP, Spertus JA, Cresci S, Hartiala J, Tang WH, Hazen SL, Allayee H, Reiner AP, Carlson CS, Kooperberg C, Jackson RD, Boerwinkle E, Lander ES, Schwartz SM, Siscovick DS, McPherson R, Tybjærg-Hansen A, Abecasis GR, Watkins H, Nickerson DA, Ardissino D, Sunyæv SR, O'Donnell CJ, Altshuler D, Gabriel S, Kathiresan S. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015;518:102-106
24. Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, Roeters van Lennep JE, Stalenhoef AF, Wiegman A, de Graaf J, Fouchier SW, Kastelein JJ, Hovingh GK. Homozygous autosomal dominant hypercholesterolæmia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015;36:560-565
25. Defesche JC. Defining the challenges of FH screening for familial hypercholesterolemia. J Clin Lipidol 2010;4:338-341
26. Damgaard D, Larsen ML, Nissen PH, Jensen JM, Jensen HK, Soerensen VR, Jensen LG, Færgeman O. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005;180: 155-160
27. Futema M, Whittall RA, Kiley A, Steel LK, Cooper JA, Badmus E, Leigh SE, Karpe F, Neil HA, Simon Broome Register G, Humphries SE. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolæmia in routine clinical practice in a UK specialist hospital lipid clinic. Atherosclerosis 2013;229: 161-168
28. Wilson BJ, Qureshi N, Santaguida P, Little J, Carroll JC, Allanson J, Raina P. Systematic review: family history in risk assessment for common diseases. Ann Intern Med 2009;151:878-885